ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

ResMed has beaten its earnings forecast in the second quarter despite concerns from investors around weight loss drugs ...

RMD's stellar second-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its ...

Higher adherence supports both reimbursement rates from payers and the resupply of masks and accessories. ResMed also plays a key role in producing clinical data that demonstrates treatment can ...